Alembic Pharma gets USFDA nod to market generic anti-fungal solution
Alembic Pharma gets USFDA nod to market generic anti-fungal solution is drawing significant interest across the industry.
The company has received final approval from the US Food & Drug Administration (USFDA) for Efinaconazole Topical Solution (10 per cent).
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Indian Energy Exchange appeals filed challenging CERC market coupling implementation
- Energy and Industrials Stocks Take the Lead as the Market Rotation Continues
- Middle East Conflict Sparks Global Market Turmoil
- India’s top 5 states leading residential real estate market in 2026
Source: Original →